Du är här

2014-04-23

Cytokinetics, Inc.: Cytokinetics to Host Investor Breakfast and Webcast Following Presentation of Results from BENEFIT-ALS

South San Francisco, CA, April 23, 2014

-
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it plans to
host an Investor Breakfast and Webcast on the morning following the
presentation of the results from the BENEFIT-ALS trial at the 66thAnnual
Meeting of the American Academy of Neurology. The Cytokinetics sponsored
event will be held on Wednesday, April 30thfrom 7:00 AM - 9:00 AM Eastern
Time in the Grand Ballroom of the Ritz Carlton Hotel, Philadelphia, PA. The
formal program and webcast will begin at 7:30 AM Eastern Time.

Cytokinetics will be represented by Robert I. Blum, President and Chief
Executive Officer; Dr. Andrew A. Wolff, Senior Vice President of Clinical
Research and Development and Chief Medical Officer; Dr. Fady I. Malik, Senior
Vice President, Research and Early Development; and Dr. Jinsy Andrews,
Director of Clinical Research and Medical Monitor of BENEFIT-ALS. Also
participating will be Dr. Jeremy M. Shefner, Professor and Chair, Department
of Neurology at the Upstate Medical University, State University of New York
and Principal Investigator of BENEFIT-ALS; Dr. Robert G. Miller, Clinical
Professor of Neurology and Neurological Sciences at Stanford University, and
Director of the Forbes Norris ALS Research Center at the California Pacific
Medical Center; and Dr. Merit E. Cudkowicz, Professor of Neurology, Harvard
Medical School and Chief of Neurology Service at Massachusetts General
Hospital (MGH) and Director of the ALS Clinic at MGH.

Those interested in attending in person should RSVP
toinvestor@cytokinetics.comby April 25, 2014. In addition, others may access
the live webcast of the presentation and accompanying slides by visiting the
Investor Relations section of Cytokinetics' website at www.cytokinetics.com.
The live audio of the forum will also be accessible by dialing either (866)
999-2985 (United States and Canada) or (706) 679-3078 (International) and
typing in the passcode 28937827. The webcast replay of the presentation will
be archived on the Presentations page within the Investor Relations section
of Cytokinetics' website following the event. The replay will also be
available via telephone from April 30, 2014 at 1:00 PM Eastern Time until May
7, 2014 by dialing (855) 859-2056 (United States and Canada) or (404)
537-3406 (International) and typing in the passcode 28937827.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program,omecamtiv mecarbil
, is in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide to develop and
commercializeomecamtiv mecarbil
and related compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developingtirasemtiv
, a fast skeletal muscle activator, as a potential treatment for diseases and
medical conditions associated with neuromuscular dysfunction.Tirasemtiv
is currently the subject of a Phase II clinical trials program and has been
granted orphan drug designation and fast track status by the U.S. Food and
Drug Administration and orphan medicinal product designation by the European
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis
(ALS). Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a skeletal muscle activator structurally distinct from
tirasemtiv, for non-neuromuscular indications. All of these drug candidates
have arisen from Cytokinetics' muscle biology focused research activities and
are directed towards the cytoskeleton. The cytoskeleton is a complex
biological infrastructure that plays a fundamental role within every human
cell. Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the properties
and potential benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current expectations,
but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or
delays in the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that could slow
or prevent clinical development or product approval, including risks that
current and past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information regarding
these and other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Joanna L. Goldstein
Manager, Investor Relations&Corporate Communications
(650) 624-3000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Globenewswire

HUG#1778877

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.